Eikon Therapeutics Inc 2025年度报告

OR Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES☐NO☒ Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES☐NO☒ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES☐NO☒ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 ofthis chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). YES☒NO☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financialaccounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reportingunder Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correctionof an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’sexecutive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES☐NO☒ DOCUMENTS INCORPORATED BY REFERENCE None. Table of Contents PART I Item 1.BusinessItem 1A.Risk FactorsItem 1B.Unresolved Staff CommentsItem 1C.CybersecurityItem 2.PropertiesItem 3.Legal ProceedingsItem 4.Mine Safety Disclosures PART II Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of EquitySecurities163Item 6.[Reserved]165Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations165Item 7A.Quantitative and Qualitative Disclosures About Market Risk177Item 8.Financial Statements and Supplementary Data177Item 9.Changes in and Disagreements With Accountants on Accounting and Financial Disclosure209Item 9A.Controls and Procedures209Item 9B.Other Information210Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections210 PART III Item 10.Directors, Executive Officers and Corporate Governance211Item 11.Executive Compensation217Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters232Item 13.Certain Relationships and Related Transactions, and Director Independence235Item 14.Principal Accounting Fees and Services241 PART IV Item 15.Exhibits, Financial Statement Schedules242Item 16.Form 10-K Summary245 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K (“Annual Report”) contains forward-looking statements about us and our industry within the meaningof the federal securities laws, which statements involve substantial risks and uncertainties. Forward-looking statements generally relate tofuture events or our future financial or operating performance. All statements other than statements of historical facts contained in this AnnualReport, including statements regarding our future results of operations and financial position, business strategy, product candidates, plans forand results of preclinical studies and clinical trials, research and development costs, manufacturing plans, regulatory approvals, timing andlikelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. In some cases, youcan identify forward-looking statements because they contain words such as “may,” “will,” “should,” “would,” “expects,” “plans,”“anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “pr